Recombinant Human Elongin B/Elongin C/VHL/CUL2/RBX1, CF

1 μg and 2 μg per lane of Recombinant Human VHL/ELOB/ELOC/CUL2/RBX1 Complex (Catalog # E3-655) was resolved with SDS-PAGE under reducing conditions and visualized by colloidal Coomassie Blue staining, showing bands corresponding to the individual proteins of the complex.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Elongin B/Elongin C/VHL/CUL2/RBX1, CF Summary

• Details of Functionality: Typical protein concentration for use in vitro will depend on experimental conditions.
• Source: Spodoptera frugiperda, Sf 21 (baculovirus)-derived human VHL/ELOB/ELOC/CUL2/RBX1 Complex protein
  Met1 - Asp213 (VHL), Met1 - Gln118 (ELOB), Met1 - Cys112 (ELOC), Met1 - Ala 745 with a N-terminal 10-His tag Sumo tag (CUL2), Met1 - His108 (RBX1)
• Accession #: P40337.2, Q15370.1, Q15369.1, Q13617.2, P62877.1
• Protein/Peptide Type: Recombinant Enzymes
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 25 kDa (VHL), 13.1 kDa (ELOB), 12.8 kDa (ELOC), 93 kDa (CUL2), 12 kDa (RBX1).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in HEPES, NaCl, DTT and Glycerol.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Elongin B/Elongin C/VHL/CUL2/RBX1, CF

• VHL/ELOB/ELOC/CUL2/RBX1 Complex

Background

VHL (von Hippel-Lindau disease tumor suppressor) is the substrate recognition subunit for an E3 ligase activity that ubiquitinates proteins containing hydroxyproline residues.  Targets of VHL include HIF1 alpha , beta 2 adrenergic receptor, ZHX2 and others.  In VHL-box E3 Ubiquitin ligases, VHL is bound to a heterodimer complex composed of Elongin B (ELOB) and Elongin C (ELOC) through the "BC-box motif" found in many proteins in the VHL-box and SOCS-box protein families.  ELOB/ELOC serves as an adapter between substrate recognition proteins and Cullin-2 (or Cullin-5) and RBX1 to form an active E3 ligase.  

1. Kamura T., et al. (1998) Genes & Dev.  doi: 10.1101/gad.12.24.3872
2. Okumura F., et al. (2012) Front. Oncol.  doi: 10.3389/fonc.2012.00010
3. Xie L., et al. (2009) Sci. Signaling  doi: 10.1126/scisignal.2000444
4. Zhang J., et al. (2018) Science  doi: 10.1126/science.aap8411

Publications for VHL/ELOB/ELOC/CUL2/RBX1 Complex (E3-655)(1)

Publication using E3-655

• Hoffman, M;Krum, D;Wittrup, KD; Bivalent target-binding bioPROTACs induce potent degradation of oncogenic SHP2 The Journal of biological chemistry 2024-07-30 [PMID: 39089586] (Bioassay, N/A)

Bioinformatics

• Uniprot:
  • P40337.2, Q15370.1, Q15369.1, Q13617.2, P62877.1()